CN116940564A - 制备g蛋白偶联受体调节剂的反式异构体形式的方法 - Google Patents

制备g蛋白偶联受体调节剂的反式异构体形式的方法 Download PDF

Info

Publication number
CN116940564A
CN116940564A CN202280017473.5A CN202280017473A CN116940564A CN 116940564 A CN116940564 A CN 116940564A CN 202280017473 A CN202280017473 A CN 202280017473A CN 116940564 A CN116940564 A CN 116940564A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
substituent
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280017473.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·布赫
J·P·戴维森
J·J·杰克逊
M·Y·M·高
G·涩谷
D·J·武斯特罗
A·尤耐
M·齐宾斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rapt Medical Co
Original Assignee
Rapt Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Medical Co filed Critical Rapt Medical Co
Publication of CN116940564A publication Critical patent/CN116940564A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
CN202280017473.5A 2021-02-02 2022-01-28 制备g蛋白偶联受体调节剂的反式异构体形式的方法 Pending CN116940564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144878P 2021-02-02 2021-02-02
US63/144,878 2021-02-02
PCT/US2022/014450 WO2022169696A1 (en) 2021-02-02 2022-01-28 Methods of making trans isomeric forms of g protein-coupled receptor

Publications (1)

Publication Number Publication Date
CN116940564A true CN116940564A (zh) 2023-10-24

Family

ID=80446466

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280017473.5A Pending CN116940564A (zh) 2021-02-02 2022-01-28 制备g蛋白偶联受体调节剂的反式异构体形式的方法

Country Status (12)

Country Link
US (2) US12428393B2 (https=)
EP (1) EP4288425A1 (https=)
JP (1) JP2024505561A (https=)
KR (1) KR20230152027A (https=)
CN (1) CN116940564A (https=)
AU (1) AU2022216216A1 (https=)
BR (1) BR112023015472A2 (https=)
CA (1) CA3209122A1 (https=)
IL (1) IL304519A (https=)
MX (1) MX2023009053A (https=)
TW (1) TW202246236A (https=)
WO (1) WO2022169696A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772680A (en) 1992-06-02 1998-06-30 General Surgical Innovations, Inc. Apparatus and method for developing an anatomic space for laparoscopic procedures with laparoscopic visualization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072743A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
CN111971279A (zh) * 2018-01-26 2020-11-20 拉普特医疗公司 趋化因子受体调节剂及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072743A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
CN111971279A (zh) * 2018-01-26 2020-11-20 拉普特医疗公司 趋化因子受体调节剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STÉPHANE G. OUELLET: "Enantioselective Organocatalytic Transfer Hydrogenation Reactions using Hantzsch Esters", ACCOUNTS OF CHEMICAL RESEARCH, vol. 40, 31 December 2007 (2007-12-31), pages 1327 - 1339 *

Also Published As

Publication number Publication date
TW202246236A (zh) 2022-12-01
WO2022169696A8 (en) 2023-08-31
IL304519A (en) 2023-09-01
US12428393B2 (en) 2025-09-30
AU2022216216A1 (en) 2023-08-03
JP2024505561A (ja) 2024-02-06
US20260092049A1 (en) 2026-04-02
CA3209122A1 (en) 2022-08-11
MX2023009053A (es) 2023-10-16
WO2022169696A1 (en) 2022-08-11
US20220251070A1 (en) 2022-08-11
KR20230152027A (ko) 2023-11-02
BR112023015472A2 (pt) 2023-11-07
EP4288425A1 (en) 2023-12-13
AU2022216216A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
TWI322805B (https=)
CA3062499C (en) Benzo[f]pyrido[1,2-d][1,4]oxazepine derivatives and pharmaceutical compositions thereof useful as hepatitis b virus surface antigen inhibitor
JP2004520382A (ja) ムスカリン受容体アゴニスト
EP1680418A2 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1781613A1 (en) Piperidine derivatives as histamine h3 receptor ligands
EA029060B1 (ru) Способ получения солей вортиоксетина
JP7015092B2 (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
KR102892833B1 (ko) [2-(3-플루오로-5-메탄-술포닐페녹시)에틸](프로필)아민의 제약상 허용되는 염 및 그의 용도
CN121194968A (zh) 含氮杂环类化合物及其应用
JP2020505440A (ja) Ｈｄａｃ６選択的阻害剤およびその製造方法と使用
US20260092049A1 (en) Methods of making trans isomeric forms of g protein-coupled receptor modulators
KR20110118626A (ko) 테트라하이드로트리아졸로피리딘 유도체의 염과 이의 결정
TW449591B (en) Neuroprotective compounds
JP7086075B2 (ja) Ｃｃｒ２／ｃｃｒ５受容体拮抗剤としてのビフェニル化合物
NZ248776A (en) Imidazole-substituted piperidine derivatives; pharmaceutical compositions and preparatory methods
CN115667247A (zh) 吡啶类衍生物及其应用
JPH07508756A (ja) 神経保護性３，４−ジヒドロ−（１ｈ）−キノロン化合物
TW421645B (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
EP4532483A1 (en) Cd38 modulators and uses thereof
CA3196035A1 (en) Fused tricyclic derivative and pharmaceutical application thereof
HRP20030246A2 (en) Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine hydrochloride
HK40090907A (en) Fused tricyclic derivative and pharmaceutical application thereof
WO2025146480A1 (en) 2-azabicyclo[2.1.1]hexane derivatives useful in the treatment of mitochondrial disorders
TW403744B (en) Piperidinyl compounds
EP2315762A2 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination